TITLE

India Inspections

AUTHOR(S)
Silverman, Ed
PUB. DATE
November 2013
SOURCE
Contract Pharma;Nov/Dec2013, Vol. 15 Issue 9, p30
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food & Drug Administration (FDA) is planning to inspect manufacturing plants in India to mitigate the over-the-top violations that continue to make headlines. It is said that the real issue may be that Indian drugmakers might not understand that the FDA is sending a serious signal.
ACCESSION #
91956253

 

Related Articles

  • Biomanufacturing on the rise. Wan, Jane // Pharmaceutical Technology Europe;Sep2011, Vol. 23 Issue 9, p32 

    The article provides information on the future of biomanufacturing industries of Asia. As stated, India has the highest number of U.S. Food and Drug Administration certified drug manufacturing facilities in the world which employs more than four times than the U.S. drug manufacturers and 12...

  • Metrics Sought to Ensure Drug Quality. Wechsler, Jill // Pharmaceutical Technology;Jan2014, Vol. 38 Issue 1, p18 

    The article discusses the work of regulators with the pharmaceutical manufacturers for improve systems for measuring product performance and manufacturing reliability. The author talks about the initiative of the U.S. Food and Drug Administration to define the right metrics to collect and audit....

  • More Transparency Hasn't Translated into Import Safety. Serebrov, Mari // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p1 

    The article focuses on the issue of manufacturing quality for drugs and other products imported from China, noting serious safety concerns in the U.S. It reports that 74 active import alerts involving Chinese companies have been issued by the U.S. Food and Drug Administration (FDA) due to great...

  • Should You Need FDA Approval to Make Manufacturing Changes? English, John T. // BioPharm International;Feb2007, Vol. 20 Issue 2, p70 

    The article analyzes the implications of the U.S. Food and Drug Administration's (FDA) intent to modify manufacturing practices regulations for the pharmaceutical industry. The industry is aware that FDA is trying to enforce the current good manufacturing practices regulations. It is anticipated...

  • Planning for the Last War. Miller, Jim // Pharmaceutical Technology;May2008, Vol. 32 Issue 5, p102 

    The article discusses the condition and business strategy of contract manufacturing organization (CMO), with analysis on the trend of pharmaceutical industry and market trends. It cites several factors on the downturn of CMOs including the declining sales of their clients' products and...

  • A Very Brady FDA. Hoffman, Michelle // Pharmaceutical Technology;May2010, Vol. 34 Issue 5, p12 

    The article discusses the effort of the U.S. Food and Drug Administration (FDA) to tackle process innovations with scientists in the pharmaceutical industry. It mentions the anxiety felt by pharmaceutical scientists regarding process innovations because having FDA to authorize a novel...

  • Foreign Plants are 'Ticking Time Bombs'.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p3 

    The article reports on the request of lawmakers for Food & Drug Association to get serious about budgetting ample funds for inspections of foreign manufacturing facilities that export products into the U.S. According to the Energy and Commerce, the FDA inspect U.S. drug firms once every 2.7...

  • Global Supply Chain Quality Management. Rhoades, Bob // Contract Pharma;Jan/Feb2011, Vol. 13 Issue 1, p68 

    The article reports on the enforcement of the Food and Drug Administration (FDA) on the global pharmaceutical supply chain in the U.S. It cites the factors which drive the trend towards global outsourcing which include competitiveness in the global marketplace, greater productivity and a global...

  • FDA Disappointed with RFID Use.  // Health Data Management;Aug2006, Vol. 14 Issue 8, p24 

    The article reports on the lack of progress in the use of radio frequency identification technology to track drugs and avoid counterfeits. The U.S. Food and Drug Administration is disappointed to find that the use of this technology will not be widespread by 2007 as initially expected due to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics